Search Results - "Ramies, D."

655O Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7-expressing recurrent non-small cell lung cancer (rNSCLC) by Cho, B.C., Johnson, M.L., Bar, J., Schaefer, E., Yoh, K., Zer, A., Moskovitz, M.T., Lee, S-H., Moreno Garcia, V., De Miguel Luken, M.J., Okuma, Y., Kim, J-H., Lee, C-H., Ansell, P.J., Biesdorf de Almeida, C., Saab, R., Freise, K., Ramies, D., Jeng, E., Camidge, D.R.

Get full text

Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory NHL: A phase IB/II study by Phillips, T., Brunvand, M., Chen, A. I., Essell, J., Chiappella, A., Diefenbach, C., Cheng, J., Ramies, D., Hirata, J., Morschhauser, Franck, Flinn, I. W.

Get full text

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer by Herbst, Roy S, Prager, Diane, Hermann, Robert, Fehrenbacher, Lou, Johnson, Bruce E, Sandler, Alan, Kris, Mark G, Tran, Hai T, Klein, Pam, Li, Xin, Ramies, David, Johnson, David H, Miller, Vincent A

“…Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients with…”
Get full text

Antitumor activity observed in a phase I drug–drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC) by Choueiri, T. K., Pal, S. K., Cabanillas, M. E., Ramies, D. A., Tseng, L., Holland, J. S., Morrissey, S., Dutcher, J. P.

“…Abstract only…”
Get full text

Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT) by Buckanovich, R. J., Berger, R., Sella, A., Sikic, B. I., Shen, X., Ramies, D. A., Smith, D. C., Vergote, I. B.

“…Abstract only…”
Get full text

Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy by Blum, K. A., Smith, M., Fung, H., Zalevsky, J., Combs, D., Ramies, D. A., Younes, A.

“…Abstract only 8531 Background: XmAb2513 is a novel 2 nd -generation humanized monoclonal antibody (mAb) directed against CD30 (a cell surface antigen expressed…”
Get full text

Bevacizumab: Analysis of clinical benefit in females across trials in colorectal cancer and non-small cell lung cancer by Ramies, D. A., Sandler, A., Gray, R., Giantonio, B., Brahmer, J., Lyons, B., Schiller, J.

“…Abstract only 7634 Background: Bevacizumab (Bv) has demonstrated significant improvement in overall survival (OS) in randomized trials in first- and…”
Get full text

A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer by Fehrenbacher, L., O’Neill, V., Belani, C. P., Bonomi, P., Hart, L., Melnyk, O., Sandler, A., Ramies, D., Herbst, R. S.

“…Abstract only 7062 Background: Bevacizumab is a recombinant, humanized anti-VEGF MAb. Erlotinib is a potent, reversible, highly selective and orally available…”
Get full text

Independent review of fatal interstitial lung disease (ILD) in TRIBUTE: paclitaxel + carboplatin ± erlotinib in advanced non-small cell lung cancer (NSCLC) by Gandara, D. R., Yoneda, K., Shelton, D., Beckett, L. A., Ramies, D. A., Bloss, J., Herbst, R. S.

“…Abstract only 7071 Background: ILD is a rare but serious complication of EGFR tyrosine kinase inhibitor (TKI) therapy, fatal in about 1/3 of cases. The…”
Get full text

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib by EBERHARD, David A, JOHNSON, Bruce E, KLEIN, Pam, MILLER, Vincent A, OSTLAND, Michael A, RAMIES, David A, SEBISANOVIC, Dragan, STINSON, Jeremy A, ZHANG, Yu R, SESHAGIRI, Somasekar, HILLAN, Kenneth J, AMLER, Lukas C, GODDARD, Audrey D, HELDENS, Sherry L, HERBST, Roy S, INCE, William L, JÄNNE, Pasi A, JANUARIO, Thomas, JOHNSON, David H

“…Epidermal growth factor receptor (EGFR) mutations have been associated with tumor response to treatment with single-agent EGFR inhibitors in patients with…”
Get full text

Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer by HERBST, Roy S, JOHNSON, David H, HONG, Waun K, TRAN, Hai, TSAO, Anne, DONG XIE, RAMIES, David A, MASS, Robert, SESHAGIRI, Somasekar, EBERHARD, David A, KELLEY, Sean K, SANDLER, Alan, MININBERG, Eric, CARBONE, David P, HENDERSON, Ted, KIM, Edward S, BLUMENSCHEIN, George JR, LEE, Jack J, LIU, Diane D, TRUONG, Mylene T

“…Bevacizumab (Avastin; Genentech, South San Francisco, CA) is a recombinant, humanized anti-vascular endothelial growth factor monoclonal antibody. Erlotinib…”
Get full text

Phase I/II trial of bevacizumab plus erlotinib for patients with recurrent non-small cell lung cancer: Correlation of treatment response with mutations of the EGFR tyrosine kinase gene by Tsao, A. S., Herbst, R., Sandler, A., Seshagiri, S., Wistuba, I., Henderson, T., Ramies, D., Goddard, A., Johnson, D., Eberhard, D.

“…Abstract only…”
Get full text

Weekly high-dose erlotinib in patients with non-small cell lung cancer (NSCLC): A phase I/II study by Milton, D. T., Miller, V. A., Azzoli, C. G., Dunne, M., Gomez, J. E., Heelan, R., Krug, L. M., Ramies, D., Rizvi, N. A., Kris, M. G.

“…Abstract only…”
Get full text

Weekly high-dose erlotinib in patients with non-small cell lung cancer (NSCLC): A phase I/II study by Milton, D. T., Miller, V. A., Azzoli, C. G., Dunne, M., Gomez, J. E., Heelan, R., Krug, L. M., Ramies, D., Rizvi, N. A., Kris, M. G.

“…Abstract only…”
Get full text

Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE by Miller, V. A., Herbst, R., Prager, D., Fehrenbacher, L., Hermann, R., Hoffman, P., Johnson, B., Sandler, A. B., Kris, M. G., Ramies, D.

“…Abstract only…”
Get full text

Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE by Miller, V. A., Herbst, R., Prager, D., Fehrenbacher, L., Hermann, R., Hoffman, P., Johnson, B., Sandler, A. B., Kris, M. G., Ramies, D.

“…Abstract only…”
Get full text

Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): Early termination due to increased toxicities by MESSERSMITH, Wells A, LAHERU, Daniel A, SENZER, Neil N, DONEHOWER, Ross C, GROULEFF, Paula, ROGERS, Theresa, KELLEY, Sean K, RAMIES, David A, LUM, Bert L, HIDALGO, Manuel

“…This phase I study was conducted to establish the dose-limiting toxicities and maximum-tolerated dose of erlotinib, an oral epidermal growth factor receptor…”
Get full text

414 Correlation of mutations in EGFR with clinical outcomes in NSCLC patients treated with erlotinib by Eberhard, D., Amler, L., Goddard, A., Ince, W., Januario, T., Hillan, K., Ostland, M., Ramies, D., Seshagiri, S., Klein, P.

Get full text

P1-17-10: Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Trial by Tolaney, SM, Nechushtan, H, Berger, R, Kurzrock, R, Ron, IG, Schöffski, P, Awada, A, Yasenchak, CA, Burris, HA, Ramies, DA, Shen, X, Winer, EP

“…Abstract Background: Cabozantinib is an oral, potent inhibitor of MET and VEGFR2. MET overexpression has been observed in metastatic breast cancer (MBC). High…”
Get full text